Skip to content
Home
Close Home
Open Home
Journal information
Editorial board
Operations manual
Statement on the use of AI
Editorial policies
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Close Read
Open Read
Archive
TOC Alert
Current issue
Information
Close Information
Open Information
Editorial & Peer Review
Ethical policies
Funding
Complaints and appeals
Open access and licensing
Authors
Sponsorship
Contact
Publish
Close Publish
Open Publish
Instructions to authors
Online submission
English
Home
Journal Information
Editorial Board
Operations Manual
Editorial Polices
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Archive
Toc Alert
Current issue
Information
Editorial & Peer review
Ethical policies
Funding
Procedure for complaints and/or appeals
Open access & Licensing
Authors
Sponsors
Contact
Publish
Authors Instructions
Online submission
Home
Journal Information
Editorial Board
Operations Manual
Editorial Polices
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Archive
Toc Alert
Current issue
Information
Editorial & Peer review
Ethical policies
Funding
Procedure for complaints and/or appeals
Open access & Licensing
Authors
Sponsors
Contact
Publish
Authors Instructions
Online submission
ES
EN
TOC Alert
Rosario Arechavaleta-Granell
2017
>
Volume 4 - Number 3
Sulfonylureas-associated cardiovascular disease and beta-cell dysfunction – is it time to dispel the myth?
2018
>
Volume 5 - Number 4
Guía para el uso del I131 en pacientes con cáncer diferenciado de tiroides, Sociedad Mexicana de Nutrición y Endocrinología, A.C.
2016
>
Volume 3 - Number 2
Safety considerations in the use of glucagon-like peptide-1 receptor agonists